Resistance of Herpes Simplex Virus Infections to Nucleoside Analogues in HIV-Infected Patients
Antiviral treatment of herpes simplex virus (HSV) infections with nucleoside analogues has been well established for >2 decades, but isolation of drug-resistant HSV from immunocompetent patients has remained infrequent (0.1%–0.7% of isolates) during this period. Even when drug-resistant HSV is is...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 2004-11, Vol.39 (Supplement-5), p.S248-S257 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S257 |
|---|---|
| container_issue | Supplement-5 |
| container_start_page | S248 |
| container_title | Clinical infectious diseases |
| container_volume | 39 |
| creator | Levin, Myron J. Bacon, Teresa H. Leary, Jeffry J. |
| description | Antiviral treatment of herpes simplex virus (HSV) infections with nucleoside analogues has been well established for >2 decades, but isolation of drug-resistant HSV from immunocompetent patients has remained infrequent (0.1%–0.7% of isolates) during this period. Even when drug-resistant HSV is isolated from an immunocompetent patient, this virus, with rare exceptions, is cleared normally without adverse clinical outcome. Although drug-resistant HSV is more commonly isolated from immunocompromised patients (4%–7% of isolates) and is more likely to be clinically significant, the prevalence of drug-resistant HSV even among these patients, has been stable over the past 2 decades. Despite this stable prevalence, disease due to drug-resistant HSV remains an important problem for many immunocompromised patients, including those with HIV infection. This article reviews the prevalence, pathogenesis, and implications of drug-resistant HSV infections in HIV-infected patients. |
| doi_str_mv | 10.1086/422364 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_66989494</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>4462961</jstor_id><sourcerecordid>4462961</sourcerecordid><originalsourceid>FETCH-LOGICAL-c397t-414f8b2cad4ae0f8a3da514d7a61be57cbd5e49ff769fb89e0947ea5df85337b3</originalsourceid><addsrcrecordid>eNqFkVtP3DAQha0KVG7tL6iQn3gL2Ov7I0Isu1xXLayqPtRykjEyZOPFTiT67xuUFTzyNCOdb45mziD0nZJjSrQ84ZMJk_wL2qWCqUIKQ7eGnghdcM30DtrL-YkQSjURX9EOFdxwbeQu-vsTcsidayvA0eMZpDVk_Cus1g284mVIfcbz1kPVhdhm3EV821cNxBxqwKeta-JjPwyEFs_my2IkocYL1wVou3yAtr1rMnzb1H30MD2_P5sV13cX87PT66JiRnUFp9zrclK5mjsgXjtWO0F5rZykJQhVlbUAbrxX0vhSGyCGK3Ci9lowpkq2j45G33WKL8NCnV2FXEHTuBZin62URpvh5k9BqpShWogPsEox5wTerlNYufTPUmLfIrdj5AN4uHHsyxXUH9gm4wH4MQJPuYvpXedcToykg1yM8vAGeH2XXXq2UjEl7Oz3H3tzuTDLi8XUXrH_cRuUVg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17791855</pqid></control><display><type>article</type><title>Resistance of Herpes Simplex Virus Infections to Nucleoside Analogues in HIV-Infected Patients</title><source>Jstor Complete Legacy</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Levin, Myron J. ; Bacon, Teresa H. ; Leary, Jeffry J.</creator><creatorcontrib>Levin, Myron J. ; Bacon, Teresa H. ; Leary, Jeffry J.</creatorcontrib><description>Antiviral treatment of herpes simplex virus (HSV) infections with nucleoside analogues has been well established for >2 decades, but isolation of drug-resistant HSV from immunocompetent patients has remained infrequent (0.1%–0.7% of isolates) during this period. Even when drug-resistant HSV is isolated from an immunocompetent patient, this virus, with rare exceptions, is cleared normally without adverse clinical outcome. Although drug-resistant HSV is more commonly isolated from immunocompromised patients (4%–7% of isolates) and is more likely to be clinically significant, the prevalence of drug-resistant HSV even among these patients, has been stable over the past 2 decades. Despite this stable prevalence, disease due to drug-resistant HSV remains an important problem for many immunocompromised patients, including those with HIV infection. This article reviews the prevalence, pathogenesis, and implications of drug-resistant HSV infections in HIV-infected patients.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1086/422364</identifier><identifier>PMID: 15494896</identifier><language>eng</language><publisher>United States: The University of Chicago Press</publisher><subject>Acyclovir - pharmacology ; Acyclovir - therapeutic use ; AIDS ; Animals ; Antiviral Agents - pharmacology ; Antiviral Agents - therapeutic use ; Antivirals ; Disease transmission ; Drug Resistance, Viral - genetics ; Drug Resistance, Viral - immunology ; Genetic mutation ; Herpes simplex ; Herpes Simplex - complications ; Herpes Simplex - drug therapy ; Herpes Simplex - immunology ; Herpes simplex virus ; HIV Infections - complications ; HIV Infections - immunology ; Human immunodeficiency virus ; Humans ; Immunity, Cellular ; Immunocompetence ; Immunocompromised Host ; Immunocompromised populations ; Infections ; Lesions ; Nucleosides - pharmacology ; Nucleosides - therapeutic use ; Recurrence ; Simplexvirus ; Simplexvirus - drug effects ; Simplexvirus - genetics ; Simplexvirus - pathogenicity ; Viruses</subject><ispartof>Clinical infectious diseases, 2004-11, Vol.39 (Supplement-5), p.S248-S257</ispartof><rights>Copyright 2004 The Infectious Diseases Society of America</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c397t-414f8b2cad4ae0f8a3da514d7a61be57cbd5e49ff769fb89e0947ea5df85337b3</citedby><cites>FETCH-LOGICAL-c397t-414f8b2cad4ae0f8a3da514d7a61be57cbd5e49ff769fb89e0947ea5df85337b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/4462961$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/4462961$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,776,780,799,27901,27902,57992,58225</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15494896$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Levin, Myron J.</creatorcontrib><creatorcontrib>Bacon, Teresa H.</creatorcontrib><creatorcontrib>Leary, Jeffry J.</creatorcontrib><title>Resistance of Herpes Simplex Virus Infections to Nucleoside Analogues in HIV-Infected Patients</title><title>Clinical infectious diseases</title><addtitle>Clinical Infectious Diseases</addtitle><description>Antiviral treatment of herpes simplex virus (HSV) infections with nucleoside analogues has been well established for >2 decades, but isolation of drug-resistant HSV from immunocompetent patients has remained infrequent (0.1%–0.7% of isolates) during this period. Even when drug-resistant HSV is isolated from an immunocompetent patient, this virus, with rare exceptions, is cleared normally without adverse clinical outcome. Although drug-resistant HSV is more commonly isolated from immunocompromised patients (4%–7% of isolates) and is more likely to be clinically significant, the prevalence of drug-resistant HSV even among these patients, has been stable over the past 2 decades. Despite this stable prevalence, disease due to drug-resistant HSV remains an important problem for many immunocompromised patients, including those with HIV infection. This article reviews the prevalence, pathogenesis, and implications of drug-resistant HSV infections in HIV-infected patients.</description><subject>Acyclovir - pharmacology</subject><subject>Acyclovir - therapeutic use</subject><subject>AIDS</subject><subject>Animals</subject><subject>Antiviral Agents - pharmacology</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Antivirals</subject><subject>Disease transmission</subject><subject>Drug Resistance, Viral - genetics</subject><subject>Drug Resistance, Viral - immunology</subject><subject>Genetic mutation</subject><subject>Herpes simplex</subject><subject>Herpes Simplex - complications</subject><subject>Herpes Simplex - drug therapy</subject><subject>Herpes Simplex - immunology</subject><subject>Herpes simplex virus</subject><subject>HIV Infections - complications</subject><subject>HIV Infections - immunology</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Immunity, Cellular</subject><subject>Immunocompetence</subject><subject>Immunocompromised Host</subject><subject>Immunocompromised populations</subject><subject>Infections</subject><subject>Lesions</subject><subject>Nucleosides - pharmacology</subject><subject>Nucleosides - therapeutic use</subject><subject>Recurrence</subject><subject>Simplexvirus</subject><subject>Simplexvirus - drug effects</subject><subject>Simplexvirus - genetics</subject><subject>Simplexvirus - pathogenicity</subject><subject>Viruses</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkVtP3DAQha0KVG7tL6iQn3gL2Ov7I0Isu1xXLayqPtRykjEyZOPFTiT67xuUFTzyNCOdb45mziD0nZJjSrQ84ZMJk_wL2qWCqUIKQ7eGnghdcM30DtrL-YkQSjURX9EOFdxwbeQu-vsTcsidayvA0eMZpDVk_Cus1g284mVIfcbz1kPVhdhm3EV821cNxBxqwKeta-JjPwyEFs_my2IkocYL1wVou3yAtr1rMnzb1H30MD2_P5sV13cX87PT66JiRnUFp9zrclK5mjsgXjtWO0F5rZykJQhVlbUAbrxX0vhSGyCGK3Ci9lowpkq2j45G33WKL8NCnV2FXEHTuBZin62URpvh5k9BqpShWogPsEox5wTerlNYufTPUmLfIrdj5AN4uHHsyxXUH9gm4wH4MQJPuYvpXedcToykg1yM8vAGeH2XXXq2UjEl7Oz3H3tzuTDLi8XUXrH_cRuUVg</recordid><startdate>20041101</startdate><enddate>20041101</enddate><creator>Levin, Myron J.</creator><creator>Bacon, Teresa H.</creator><creator>Leary, Jeffry J.</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20041101</creationdate><title>Resistance of Herpes Simplex Virus Infections to Nucleoside Analogues in HIV-Infected Patients</title><author>Levin, Myron J. ; Bacon, Teresa H. ; Leary, Jeffry J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c397t-414f8b2cad4ae0f8a3da514d7a61be57cbd5e49ff769fb89e0947ea5df85337b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Acyclovir - pharmacology</topic><topic>Acyclovir - therapeutic use</topic><topic>AIDS</topic><topic>Animals</topic><topic>Antiviral Agents - pharmacology</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Antivirals</topic><topic>Disease transmission</topic><topic>Drug Resistance, Viral - genetics</topic><topic>Drug Resistance, Viral - immunology</topic><topic>Genetic mutation</topic><topic>Herpes simplex</topic><topic>Herpes Simplex - complications</topic><topic>Herpes Simplex - drug therapy</topic><topic>Herpes Simplex - immunology</topic><topic>Herpes simplex virus</topic><topic>HIV Infections - complications</topic><topic>HIV Infections - immunology</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Immunity, Cellular</topic><topic>Immunocompetence</topic><topic>Immunocompromised Host</topic><topic>Immunocompromised populations</topic><topic>Infections</topic><topic>Lesions</topic><topic>Nucleosides - pharmacology</topic><topic>Nucleosides - therapeutic use</topic><topic>Recurrence</topic><topic>Simplexvirus</topic><topic>Simplexvirus - drug effects</topic><topic>Simplexvirus - genetics</topic><topic>Simplexvirus - pathogenicity</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Levin, Myron J.</creatorcontrib><creatorcontrib>Bacon, Teresa H.</creatorcontrib><creatorcontrib>Leary, Jeffry J.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Levin, Myron J.</au><au>Bacon, Teresa H.</au><au>Leary, Jeffry J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Resistance of Herpes Simplex Virus Infections to Nucleoside Analogues in HIV-Infected Patients</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clinical Infectious Diseases</addtitle><date>2004-11-01</date><risdate>2004</risdate><volume>39</volume><issue>Supplement-5</issue><spage>S248</spage><epage>S257</epage><pages>S248-S257</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><abstract>Antiviral treatment of herpes simplex virus (HSV) infections with nucleoside analogues has been well established for >2 decades, but isolation of drug-resistant HSV from immunocompetent patients has remained infrequent (0.1%–0.7% of isolates) during this period. Even when drug-resistant HSV is isolated from an immunocompetent patient, this virus, with rare exceptions, is cleared normally without adverse clinical outcome. Although drug-resistant HSV is more commonly isolated from immunocompromised patients (4%–7% of isolates) and is more likely to be clinically significant, the prevalence of drug-resistant HSV even among these patients, has been stable over the past 2 decades. Despite this stable prevalence, disease due to drug-resistant HSV remains an important problem for many immunocompromised patients, including those with HIV infection. This article reviews the prevalence, pathogenesis, and implications of drug-resistant HSV infections in HIV-infected patients.</abstract><cop>United States</cop><pub>The University of Chicago Press</pub><pmid>15494896</pmid><doi>10.1086/422364</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2004-11, Vol.39 (Supplement-5), p.S248-S257 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66989494 |
| source | Jstor Complete Legacy; Oxford University Press Journals All Titles (1996-Current); MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Acyclovir - pharmacology Acyclovir - therapeutic use AIDS Animals Antiviral Agents - pharmacology Antiviral Agents - therapeutic use Antivirals Disease transmission Drug Resistance, Viral - genetics Drug Resistance, Viral - immunology Genetic mutation Herpes simplex Herpes Simplex - complications Herpes Simplex - drug therapy Herpes Simplex - immunology Herpes simplex virus HIV Infections - complications HIV Infections - immunology Human immunodeficiency virus Humans Immunity, Cellular Immunocompetence Immunocompromised Host Immunocompromised populations Infections Lesions Nucleosides - pharmacology Nucleosides - therapeutic use Recurrence Simplexvirus Simplexvirus - drug effects Simplexvirus - genetics Simplexvirus - pathogenicity Viruses |
| title | Resistance of Herpes Simplex Virus Infections to Nucleoside Analogues in HIV-Infected Patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T15%3A55%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Resistance%20of%20Herpes%20Simplex%20Virus%20Infections%20to%20Nucleoside%20Analogues%20in%20HIV-Infected%20Patients&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Levin,%20Myron%20J.&rft.date=2004-11-01&rft.volume=39&rft.issue=Supplement-5&rft.spage=S248&rft.epage=S257&rft.pages=S248-S257&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1086/422364&rft_dat=%3Cjstor_proqu%3E4462961%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17791855&rft_id=info:pmid/15494896&rft_jstor_id=4462961&rfr_iscdi=true |